Literature DB >> 8947491

Phosphorylation and activation of p42 and p44 mitogen-activated protein kinase are required for the P2 purinoceptor stimulation of endothelial prostacyclin production.

V Patel1, C Brown, A Goodwin, N Wilkie, M R Boarder.   

Abstract

Extracellular ATP and ADP, released from platelets and other sites stimulate the endothelial production of prostacyclin (PGI2) by acting on G-protein-coupled P2Y2 and P2Y2 purinoceptors, contributing to the maintenance of a non-thrombogenic surface. The mechanism, widely described as being dependent on elevated cytosolic [Ca2+], also requires protein tyrosine phosphorylation. Here we show that activation of both these P2 receptor types leads to the tyrosine phosphorylation and activation of both the p42 and p44 forms of mitogen-activated protein kinase (MAPK). 2-Methylthio-ATP and UTP, selectively activating P2Y1 and P2Y2 purinoceptors respectively, and ATP, a non-selective agonist at these two receptors, stimulate the tyrosine phosphorylation of both p42mapk and p44mapk, as revealed by Western blots with an antiserum specific for the tyrosine-phosphorylated forms of the enzymes. By using separation on Resource Q columns, peptide kinase activity associated with the phosphorylated MAPK enzymes distributes into two peaks, one mainly p42mapk and one mainly p44mapk, both of which are stimulated by ATP with respect to kinase activity and phospho-MAPK immunoreactivity. Stimulation of P2Y1 or P2Y2 purinoceptors leads to a severalfold increase in PGI2 efflux; this was blocked in a dose-dependent manner by the selective MAPK kinase inhibitor PD98059. This drug also blocked the agonist-stimulated increase in phospho-MAPK immunoreactivity for both p42mapk and p44mapk but left the phospholipase C response to P2 agonists essentially unchanged. Olomoucine has been reported to inhibit p44mapk activity. Here we show that in the same concentration range olomoucine inhibits activity in both peaks from the Resource Q column and also the agonist stimulation of 6-keto-PGF1, but has no effect on agonist-stimulated phospho-MAPK immunoreactivity. These results provide direct evidence for the involvement of p42 and p44 MAPK in the PGI2 response of intact endothelial cells: we have shown that both the endothelial P2Y purinoceptors are linked to activation of MAPK, and that activation of this pathway is a requirement for the stimulation by ATP/ADP of endothelial PGI2 production.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8947491      PMCID: PMC1217921          DOI: 10.1042/bj3200221

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  41 in total

1.  Inhibition of MAP kinase kinase (MEK) blocks endothelial PGI2 release but has no effect on von Willebrand factor secretion or E-selectin expression.

Authors:  C P Wheeler-Jones; M J May; R A Houliston; J D Pearson
Journal:  FEBS Lett       Date:  1996-06-17       Impact factor: 4.124

2.  Characteristics of the P2 purinoceptor that mediates prostacyclin production by pig aortic endothelial cells.

Authors:  L Needham; N J Cusack; J D Pearson; J L Gordon
Journal:  Eur J Pharmacol       Date:  1987-02-10       Impact factor: 4.432

3.  Stimulation by the nucleotides, ATP and UTP of mitogen-activated protein kinase in EAhy 926 endothelial cells.

Authors:  A Graham; A McLees; C Kennedy; G W Gould; R Plevin
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Stimulation of prostaglandin production through purinoceptors on cultured porcine endothelial cells.

Authors:  J D Pearson; L L Slakey; J L Gordon
Journal:  Biochem J       Date:  1983-07-15       Impact factor: 3.857

5.  Culture of arterial endothelial cells: characterization and growth of bovine aortic cells.

Authors:  F M Booyse; B J Sedlak; M E Rafelson
Journal:  Thromb Diath Haemorrh       Date:  1975-12-15

6.  Dual effect of beta-adrenergic receptors on mitogen-activated protein kinase. Evidence for a beta gamma-dependent activation and a G alpha s-cAMP-mediated inhibition.

Authors:  P Crespo; T G Cachero; N Xu; J S Gutkind
Journal:  J Biol Chem       Date:  1995-10-20       Impact factor: 5.157

7.  Maximal epidermal growth-factor-induced cytosolic phospholipase A2 activation in vivo requires phosphorylation followed by an increased intracellular calcium concentration.

Authors:  C G Schalkwijk; M A van der Heijden; G Bunt; R Maas; L G Tertoolen; P M van Bergen en Henegouwen; A J Verkleij; H van den Bosch; J Boonstra
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

8.  Evidence for requirement of tyrosine phosphorylation in endothelial P2Y- and P2U- purinoceptor stimulation of prostacyclin release.

Authors:  A Bowden; V Patel; C Brown; M R Boarder
Journal:  Br J Pharmacol       Date:  1995-11       Impact factor: 8.739

9.  Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum.

Authors:  A R Schievella; M K Regier; W L Smith; L L Lin
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

10.  PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo.

Authors:  D R Alessi; A Cuenda; P Cohen; D T Dudley; A R Saltiel
Journal:  J Biol Chem       Date:  1995-11-17       Impact factor: 5.157

View more
  3 in total

Review 1.  P2 receptor subtypes in the cardiovascular system.

Authors:  S P Kunapuli; J L Daniel
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

2.  Osmotic cell swelling-induced ATP release mediates the activation of extracellular signal-regulated protein kinase (Erk)-1/2 but not the activation of osmo-sensitive anion channels.

Authors:  T Van der Wijk; H R De Jonge; B C Tilly
Journal:  Biochem J       Date:  1999-11-01       Impact factor: 3.857

3.  P(2Y) purinoceptor subtypes recruit different mek activators in astrocytes.

Authors:  G Lenz; C Gottfried; Z Luo; J Avruch; R Rodnight; W J Nie; Y Kang; J T Neary
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.